Smallpox and live-virus vaccination in transplant recipients

American Journal of Transplantation

Volumn 3, Issue 7, 2003, Pages 786-793

  Fishman, Jay A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bioterrorism; Chickenpox; Immunocompromised host; Organ transplant; Smallpox; Vaccine; Vaccinia; Varicella; Variola; Virus

Indexed keywords

CHICKENPOX VACCINE; IMMUNOGLOBULIN; LIVE VACCINE; SMALLPOX VACCINE; VACCINIA VACCINE;

BIOLOGICAL WARFARE; CHICKENPOX; COMA; CONFUSION; DRUG EFFECT; ECZEMA; ENCEPHALOMYELITIS; ERYTHEMA MULTIFORME; FETUS WASTAGE; FEVER; HUMAN; IMMUNE DEFICIENCY; LETHARGY; LYMPHADENOPATHY; ORGAN TRANSPLANTATION; PREMATURITY; RASH; RECIPIENT; SEIZURE; SHORT SURVEY; SKIN INDURATION; SMALLPOX; STEVENS JOHNSON SYNDROME; SUPERINFECTION; VACCINATION; VACCINATION REACTION; VACCINIA;

BIOTERRORISM; CROSS INFECTION; HUMANS; IMMUNE SYSTEM DISEASES; SMALLPOX; SMALLPOX VACCINE; TRANSPLANTATION; VACCINIA VIRUS;

EID: 0038351957     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00145.x     Document Type: Short Survey

References (57)

1. Stearn EW, Stearn AE. The Effect of Smallpox on the Destiny of the Amerindian. Boston, MA: Bruce Humphries; 1945.
2. Alibek K. Biohazard. New York NY: Random House; 1999.
3. Henderson DA, Inglesby TV, Bartlett JG et al. Smallpox as a biological weapon, medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281: 2127-2137.
4. Henderson DA. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 2002; 34: 79-83.
5. Slater PE, Anis E, Leventhal A. Preparation for an outbreak of smallpox in Israel. Isr Med Assoc J 2002; 4: 507-512.
6. CDC. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb Mortal Wkly Rep 2002; 50 (RR10): 1-25.
7. Brundtland GH. Statement to the press by the director general of the World Health Organization: updated guidance on smallpox vaccination. October 2, 2001. Geneva: World Health Organization; 2001.
8. Breman JG. Diagnosis and management of smallpox. [Comment]. N Engl J Med Online 2002; 346: 1323-1325.
9. Albert MR, Ostheimer KG, Liewehr DJ, Steinberg SM, Breman JG. Smallpox manifestations and survival during the Boston epidemic of 1901-03. Ann Intern Med Online 2002; 137: 993-1000.
10. Henderson DA. Smallpox: clinical and epidemiologic features. [comment]. Emerg Infect Dis 1999; 5: 540-546.
11. Franz DR, Jahrling PB, McClain DJ et al. Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med 2001; 21: 435-473.
12. Dixon CW. Smallpox. London: J & A Churchiil Ltd; 1962.
13. Henderson DA. Smallpox: clinical and epidemiologic features. Med Health R I 2002; 85: 107-108.
14. Rao AR. Smallpox. Bombay: Kothari Book Depot; 1972.
15. Mehta BC, Doctor RG, Purandare NM, Patel JC. Hemorrhagic smallpox. A study of 22 cases to determine the cause of bleeding. Indian J Med Sci 1967; 21: 518-523.
16. Mitra M, Bhattacharya DK. Some observations on haemorrhagic smallpox (Type I). J Indian Med Assoc 1976; 67: 237-240.
17. Downie AW, Fedson DS, Saint Vincent L, Rao AR, Kempe CH. Haemorrhagic smallpox. J Hyg 1969; 67: 619-629.
18. Martin DB. The cause of death in smallpox: an examination of the pathology record. Mil Med 2002; 167: 546-551.
19. Koplan JP, Foster SO. Smallpox: clinical types, causes of death, and treatment. J Infect Dis 1979; 140: 440-441.
20. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001; 14: 382-397.
21. Larsson M, Fonteneau JF, Somersan S et al. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells.[erratum appears in Eur J Immunol 2002; 32 (1): 307]. Eur J Immunol 2001; 31: 3432-3442.
22. Yang S, Kittlesen D, Slingluff CL Jr, Vervaert CE, Seigler HF, Darrow TL. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 2000; 164: 4204-4211.
23. Vanderplasschen A, Hollinshead M, Smith GL. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 1997; 78: 2041-2048.
24. Di Nicola M, Siena S, Bregni M et al. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther 1998; 5: 350-356.
25. Drillien R, Spehner D, Bohbot A, Hanau D. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 2000; 268: 471-481.
26. Engelmayer J, Larsson M, Subklewe M et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999; 163: 6762-6768.
27. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Philos Trans R Soc Lond B Biol Sci 2001; 356: 957-977.
28. Asanuma H, Rinki M, Sharp M et al. Immunisations in solid-organ transplant recipients. N Engl J Med 2002; 347: 26-34.
29. Stark K, Gunther M, Schonfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet 2002; 359: 957-965.
30. Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000; 30: 857-869.
31. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998; 11: 1-26.
32. LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 1996; 174 (Suppl. 3): S320-S323.
33. Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8: 190-192.
34. Sharrar RG, LaRussa P, Galea SA et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19: 916-923.
35. Asanuma H, Rinki M, Sharp M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med Online 2002; 347: 26-34.
36. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 89-93.
37. King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633-636.
38. Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69: 2449-2451.
39. Sepkowitz KA. How contagious is vaccinia? N Engl J Med 2003; 348: 1-8.
40. Frey SE, Newman FK, Cruz J et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346: 1275-1280.
41. Haim M, Gdalevich M, Mimouni D, Ashkenazi I, Shemer J. Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991-96. A comparison with previous surveys. Mil Med 2000; 165: 287-289.
42. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55: 342-347.
43. Dick G. Smallpox: a reconsideration of public health policies. Prog Med Virol 1966; 8: 1-29.
44. Zagury D. Anti HIV cellular immunotherapy in AIDS. Lancet 1991; 338: 694-695.
45. Read D, Neff J, Blumberg SJ, Stein RE, Sharp V, Newacheck PW et al. Contact vaccinia - transmission of vaccinia from smallpox vaccination. Ambulatory Pediatrics 2002; 2: 49-57.
46. Neff JM, Levine RH, Lane JM et al. Complications of smallpox vaccination United States 1963. II. Results obtained by four statewide surveys. Pediatrics 1967; 39: 916-923.
47. Neff JM, Lane JM, Pert JH, Moore R, Millar JD, Henderson DA. Complications of smallpox vaccination. I. National survey in the United States, 1963. N Engl J Med 1967; 276: 125-132.
48. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA 2002; 288: 1901-1905.
49. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122: 303-309.
50. Dixon MF. Progressive vaccinia complicating lymphosarcoma. J Pathol 1970; 100: 53-67.
51. Dixon MF. Smallpox vaccination. Br Med J 1970; 2: 539.
52. Tignor GH, Kende M, Hanham CA. Chemotherapeutic prevention of complications caused by vaccinia virus-vectored immunogen. Ann N Y Acad Sci 1992; 653: 334-343.
53. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Effective Clinical Practice 2002; 5: 84-90.
54. Sharp JC, Fletcher WB. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet 1973; 1 (7804): 656-659.
55. Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997; 25: 911-914.
56. Newman FK, Cruz J, Shelton WB et al. Smallpox vaccination policy - the need for dialogue. [Commentl. N Engl J Med 2002; 346: 1275-1280.
57. Fauci AS. Smallpox vaccination policy - the need for dialogue. [Comment]. N Engl J Med Online 2002; 346: 1319-1320.